Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. Expression of HAS in patients with fibrosis.
  • Fig. S2. Expression of HA and Has expression in mouse liver cells.
  • Fig. S3. Increased susceptibility to BDL- or CCl4-induced liver fibrosis in ASMA-HAS2 Tg mice.
  • Fig. S4. Generation of HSC-specific Has2 knockout mice.
  • Fig. S5. Effect of HSC-specific Has2 deficiency on DDC-induced liver fibrosis.
  • Fig. S6. No effect of HSC-specific Has2 deletion on CDHFD-mediated fat accumulation or glucose intolerance.
  • Fig. S7. Cd44 and Tlr4 mRNA expression in in vivo–activated HSCs.
  • Fig. S8. HA concentration in the supernatant of WT HSCs or HAS2 Tg HSCs.
  • Fig. S9. Notch1 and its target gene Hes1 mRNA expression.
  • Fig. S10. Jagged-1 expression.
  • Fig. S11. Inhibition of BDL-induced HSC activation and macrophage infiltration by 4-MU treatment.
  • Table S1. Sequence of primers used for qPCR.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Data file S1 (Microsoft Excel format). Individual subject-level data.